Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
← catalyst calendarSponsored by Omeros Corporation (industry) · OMER — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
6
Countries
Lithuania, New Zealand, Poland +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-01 | actual | When the study began enrolling |
| Primary completion | Jan 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- C3 Glomerulopathy
- Idiopathic Immune Complex-Mediated Glomerulonephritis
Intervention
- Drug: OMS906 study drug — also filed as OMS906
Primary outcome
what the primary-completion date above is the date OFTo assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN.
measured 48 weeks
Permalink · OMER's whole pipeline · Catalyst calendar · Every registered study · What changed